Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

(HZNP)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-26 pm EST
111.25 USD   -1.55%
12:48pWarren tells FTC she is "particularly concerned" about Amgen and Indivior deals
RE
01/25Horizon Therapeutics Investor Alert By The Former Attorney General Of Louisiana : Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP
BU
01/24Rule 17 Announcement - Horizon Therapeutics plc
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sector Update: Healthcare Stocks Fall Wednesday but Outperform Most Sectors

11/02/2022 | 03:01pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ARCTURUS THERAPEUTICS HOLDINGS INC. -0.10% 20 Delayed Quote.18.04%
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY -1.55% 111.25 Delayed Quote.-0.70%
NASDAQ COMPOSITE 1.76% 11512.41 Real-time Quote.8.09%
OMNICELL, INC. 2.48% 55.8 Delayed Quote.5.02%
TENET HEALTHCARE CORPORATION 2.18% 51.66 Delayed Quote.3.63%
All news about HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
12:48pWarren tells FTC she is "particularly concerned" about Amgen and Indivior deals
RE
01/25Horizon Therapeutics Investor Alert : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
01/24Rule 17 Announcement - Horizon Therapeutics plc
AQ
01/23Rule 17 (b) Announcement – Horizon Therapeutics plc
BU
01/23Rule 17 (a) Announcement – Horizon Therapeutics plc
BU
01/19Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatme..
AQ
01/18Horizon Therapeutics Reports Positive Data From Phase 2 Trial of Dazodalibep to Treat S..
MT
01/18Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatme..
BU
01/18Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatme..
CI
01/18Insider Sell: Horizon Therapeutics
MT
More news
Analyst Recommendations on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
More recommendations
Financials (USD)
Sales 2022 3 605 M - -
Net income 2022 530 M - -
Net Debt 2022 182 M - -
P/E ratio 2022 48,9x
Yield 2022 -
Capitalization 25 808 M 25 808 M -
EV / Sales 2022 7,21x
EV / Sales 2023 6,22x
Nbr of Employees 2 095
Free-Float 97,9%
Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Duration : Period :
Horizon Therapeutics Public Limited Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 113,00 $
Average target price 120,11 $
Spread / Average Target 6,29%
EPS Revisions
Managers and Directors
Timothy P. Walbert Chairman, President & Chief Executive Officer
Aaron L. Cox Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman CMO, Executive VP-Development & Regulatory Affairs
Michael A. DesJardin Executive VP-Technical Operations & Quality
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Sector and Competitors
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-0.70%25 808
JOHNSON & JOHNSON-4.72%443 181
ELI LILLY AND COMPANY-5.32%332 306
NOVO NORDISK A/S1.07%313 303
ROCHE HOLDING AG1.07%281 267
MERCK & CO., INC.-2.13%275 319